View Item 

Show simple item record

Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis
dc.contributor.authorCho, Hyungseok
dc.contributor.authorChung, Jae Il
dc.contributor.authorKim, Jinho
dc.contributor.authorSeo, Won Ik
dc.contributor.authorLee, Chan Ho
dc.contributor.authorMorgan, Todd M.
dc.contributor.authorByun, Seok‐soo
dc.contributor.authorChung, Jae‐seung
dc.contributor.authorHan, Ki‐ho
dc.date.accessioned2021-03-02T21:43:44Z
dc.date.available2022-03-02 16:43:43en
dc.date.available2021-03-02T21:43:44Z
dc.date.issued2021-02
dc.identifier.citationCho, Hyungseok; Chung, Jae Il; Kim, Jinho; Seo, Won Ik; Lee, Chan Ho; Morgan, Todd M.; Byun, Seok‐soo ; Chung, Jae‐seung ; Han, Ki‐ho (2021). "Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis." Cancer Science 112(2): 859-870.
dc.identifier.issn1347-9032
dc.identifier.issn1349-7006
dc.identifier.urihttps://hdl.handle.net/2027.42/166368
dc.description.abstractWe aimed to isolate circulating tumor cells (CTCs) using a microfluidic technique with a novel lateral magnetophoretic microseparator. Prostate cancer- specific gene expressions were evaluated using mRNA from the isolated CTCs. A CTC- based multigene model was then developed for identifying advanced prostate cancer. Peripheral blood samples were obtained from five healthy donors and patients with localized prostate cancer (26 cases), metastatic hormone- sensitive prostate cancer (mHSPC, 10 cases), and metastatic castration- resistant prostate cancer (mCRPC, 28 cases). CTC recovery rate and purity (enriched CTCs/total cells) were evaluated according to cancer stage. The areas under the curves of the six gene expressions were used to evaluate whether multigene models could identify mHSPC or mCRPC. The number of CTCs and their purity increased at more advanced cancer stages. In mHSPC/mCRPC cases, the specimens had an average of 27.5 CTCs/mL blood, which was 4.2 à  higher than the isolation rate for localized disease. The CTC purity increased from 2.1% for localized disease to 3.8% for mHSPC and 6.7% for mCRPC, with increased CTC expression of the genes encoding prostate- specific antigen (PSA), prostate- specific membrane antigen (PSMA), and cytokeratin 19 (KRT19). All disease stages exhibited expression of the genes encoding androgen receptor (AR) and epithelial cell adhesion molecule (EpCAM), although expression of the AR- V7 variant was relatively rare. Relative to each gene alone, the multigene model had better accuracy for predicting advanced prostate cancer. Our lateral magnetophoretic microseparator can be used for identifying prostate cancer biomarkers. In addition, CTC- based genetic signatures may guide the early diagnosis of advanced prostate cancer.CTCs have useful biological information for understanding the prostate cancer aggressiveness. CTC- based gene signatures have potential for early diagnosis of metastatic prostate cancer. Multigene profile (AR, AR- V7, PSA, PSMA, EpCAM, and KRT19) may guide the diagnosis and treatment of metastatic prostate cancer.
dc.publisherWiley Periodicals, Inc.
dc.publisherLippincott Williams & Wilkins
dc.subject.otherprostate cancer
dc.subject.othermagnetophoresis
dc.subject.otherprognostication
dc.subject.othercirculating tumor cells
dc.subject.othergenetic signature
dc.titleMultigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166368/1/cas14745.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166368/2/cas14745_am.pdf
dc.identifier.doi10.1111/cas.14745
dc.identifier.sourceCancer Science
dc.identifier.citedreferenceScher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration- resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10: 233 - 239.
dc.identifier.citedreferenceOzkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen- dependent and- independent sorting of rare circulating tumor cells. Sci Trans Med. 2013; 5: 179ra47.
dc.identifier.citedreferenceLi P, Mao Z, Peng Z, et al. Acoustic separation of circulating tumor cells. Proc Natl Acad Sci. 2015; 112: 4970 - 4975.
dc.identifier.citedreferenceAugustsson P, Magnusson C, Nordin M, et al. Microfluidic, label- free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem. 2012; 84: 7954 - 7962.
dc.identifier.citedreferenceStott SL, Hsu C- H, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex- generating herringbone- chip. Proc Natl Acad Sci. 2010; 107: 18392 - 18397.
dc.identifier.citedreferenceCho H, Kim J, Jeon C- W, et al. A disposable microfluidic device with a reusable magnetophoretic functional substrate for isolation of circulating tumor cells. Lab Chip. 2017; 17: 4113 - 4123.
dc.identifier.citedreferenceMa Y, Luk A, Young FP, et al. Droplet digital PCR based androgen receptor variant 7 (AR- V7) detection from prostate cancer patient blood biopsies. Int J Mol Sci. 2016; 17: 1264.
dc.identifier.citedreferenceHarrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361 - 387.
dc.identifier.citedreferenceWintrobe MM. Examiniation of the blood and bone marrow. In: Wintrobe’s clinical hematology. Vol. 1, 12 th ed. Lippincott Williams & Wilkins; 2008: 2 - 7.
dc.identifier.citedreferenceTryfonidis K, Kafousi M, Perraki M, et al. Detection of circulating cytokeratin- 19 mRNA- positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. Clin Breast Cancer. 2014; 14: 442 - 450.
dc.identifier.citedreferenceMarkou A, Strati A, Malamos N, et al. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem. 2011; 57: 421 - 430.
dc.identifier.citedreferenceTsongalis GJ, Peterson JD, de Abreu FB, et al. Routine use of the Ion Torrent AmpliSeq- ¢ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin chem Lab Med. 2014; 52: 707 - 714.
dc.identifier.citedreferenceChin EL, da Silva C, Hegde M. Assessment of clinical analytical sensitivity and specificity of next- generation sequencing for detection of simple and complex mutations. BMC Genet. 2013; 14: 6.
dc.identifier.citedreferenceScher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual- level surrogate for survival in metastatic castration- resistant prostate cancer. J Clin Oncol. 2015; 33: 1348 - 1355.
dc.identifier.citedreferenceChung J- S, Wang Y, Henderson J, et al. Circulating tumor cell- based molecular classifier for predicting resistance to abiraterone and enzalutamide in metastatic castration- resistant prostate cancer. Neoplasia. 2019; 21: 802 - 809.
dc.identifier.citedreferenceAzad AA, Volik SV, Wyatt AW, et al. Androgen receptor gene aberrations in circulating cell- free DNA: biomarkers of therapeutic resistance in castration- resistant prostate cancer. Clin Cancer Res. 2015; 21: 2315 - 2324.
dc.identifier.citedreferenceKohli M, Li J, Du M, et al. Prognostic association of plasma cell- free DNA- based androgen receptor amplification and circulating tumor cells in pre- chemotherapy metastatic castration- resistant prostate cancer patients. Prostate Cancer and Prostatic Dis. 2018; 21: 411 - 418.
dc.identifier.citedreferenceKantoff PW, Halabi S, Farmer DA, et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate- specific antigen in men with hormone- refractory prostate cancer. J Clin Oncol. 2001; 19: 3025 - 3028.
dc.identifier.citedreferenceRoss RW, Manola J, Hennessy K, et al. Prognostic significance of baseline reverse transcriptase- PCR for prostate- specific antigen in men with hormone- refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005; 11: 5195 - 5198.
dc.identifier.citedreferenceAutio KA, Dreicer R, Anderson J, et al. Safety and efficacy of BIND- 014, a docetaxel nanoparticle targeting prostate- specific membrane antigen for patients with metastatic castration- resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018; 4: 1344 - 1351.
dc.identifier.citedreferenceSweat SD, Pacelli A, Murphy GP, et al. Prostate- specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998; 52: 637 - 640.
dc.identifier.citedreferenceLawal IO, Bruchertseifer F, Vorster M, et al. Prostate- specific membrane antigen- targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020; 30: 98 - 105.
dc.identifier.citedreferenceUdovicich C, Perera M, Hofman MS, et al. 68Ga- prostate- specific membrane antigen- positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends. Prostate Int. 2017; 5: 125 - 129.
dc.identifier.citedreferenceHofman MS, Lawrentschuk N, Francis RJ, et al. Prostate- specific membrane antigen PET- CT in patients with high- risk prostate cancer before curative- intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi- centre study. Lancet. 2020; 395: 1208 - 1216.
dc.identifier.citedreferenceFendler WP, Calais J, Eiber M, et al. Assessment of 68Ga- PSMA- 11 PET accuracy in localizing recurrent prostate cancer: a prospective single- arm clinical trial. JAMA Oncol. 2019; 5: 856 - 863.
dc.identifier.citedreferencePerera M, Papa N, Roberts M, et al. Gallium- 68 prostate- specific membrane antigen positron emission tomography in advanced prostate cancer- updated diagnostic utility, sensitivity, specificity, and distribution of prostate- specific membrane antigen- avid lesions: a systematic review and meta- analysis. Eur Urol. 2019; 77: 403 - 417.
dc.identifier.citedreferenceCalais J, Ceci F, Eiber M, et al. 18F- fluciclovine PET- CT and 68Ga- PSMA- 11 PET- CT in patients with early biochemical recurrence after prostatectomy: a prospective, single- centre, single- arm, comparative imaging trial. Lancet Oncol. 2019; 20: 1286 - 1294.
dc.identifier.citedreferenceSinghal U, Wang Y, Henderson J, et al. Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature. Mol Cancer Res. 2018; 16 ( 4 ): 643 - 654.
dc.identifier.citedreferenceKozminsky M, Fouladdel S, Chung J- S, et al. Detection of CTC Clusters and a Dedifferentiated RNA- Expression Survival Signature in Prostate Cancer. Adv Sci (Weinh). 2018; 6: 1801254.
dc.identifier.citedreferenceParker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018; 392: 2353 - 2366.
dc.identifier.citedreferenceShen MM, Rubin MA. Prostate cancer research at the crossroads. Cold Spring Harb Perspect Med. 2019; 9: a036277.
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394 - 424.
dc.identifier.citedreferenceBroncy L, Paterlini- Bréchot P. Clinical impact of circulating tumor cells in patients with localized prostate cancer. Cells. 2019; 8: 676.
dc.identifier.citedreferenceNuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration- resistant prostate cancer in the era of precision oncology. Eur Urol. 2019; 75: 88 - 99.
dc.identifier.citedreferencePantel K, Hille C, Scher HI. Circulating tumor cells in prostate cancer: from discovery to clinical utility. Clin Chem. 2019; 65: 87 - 99.
dc.identifier.citedreferenceMiyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells- monitoring treatment response in prostate cancer. Nat Rev Clin oncol. 2014; 11: 401 - 412.
dc.identifier.citedreferenceDanila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011; 17: 3903 - 3912.
dc.identifier.citedreferenceDe Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration- resistant prostate cancer. Clin Cancer Res. 2008; 14: 6302 - 6309.
dc.identifier.citedreferenceDanila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration- resistant prostate cancer. Clin Cancer Res. 2007; 13: 7053 - 7058.
dc.identifier.citedreferenceSciarra A, Gentilucci A, Silvestri I, et al. Androgen receptor variant 7 (AR- V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review. Medicine. 2019; 98: e15608.
dc.identifier.citedreferenceAntonarakis ES, Lu C, Wang H, et al. AR- V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028 - 1038.
dc.identifier.citedreferenceOkegawa T, Ninomiya N, Masuda K, et al. AR- V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration- resistant prostate cancer patients. Prostate. 2018; 78: 576 - 582.
dc.identifier.citedreferenceScher HI, Lu D, Schreiber NA, et al. Association of AR- V7 on circulating tumor cells as a treatment- specific biomarker with outcomes and survival in castration- resistant prostate cancer. JAMA oncology. 2016; 2: 1441 - 1449.
dc.identifier.citedreferenceMeyer CP, Pantel K, Tennstedt P, et al. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 2016; 34 ( 235 ): e11 - e16.
dc.identifier.citedreferenceThalgott M, Rack B, Horn T, et al. Detection of circulating tumor cells in locally advanced high- risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy. Anticancer Res. 2015; 35: 5679 - 5685.
dc.identifier.citedreferenceDavis JW, Nakanishi H, Kumar VS, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008; 179: 2187 - 2191.
dc.identifier.citedreferenceBeltran H, Jendrisak A, Landers M, et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin Cancer Res. 2016; 22: 1510 - 1519.
dc.identifier.citedreferenceDago AE, Stepansky A, Carlsson A, et al. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9: e101777.
dc.identifier.citedreferenceSteinestel J, Luedeke M, Arndt A, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015; 10: 4213 - 4223.
dc.identifier.citedreferenceMagnusson C, Augustsson P, Lenshof A, et al. Clinical- scale cell- surface- marker independent acoustic microfluidic enrichment of tumor cells from blood. Anal Chem. 2017; 89: 11954 - 11961.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cas14745.pdf
Size:
1.872MB
Format:
PDF
View/Open
Name:
cas14745_am.pdf
Size:
529.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.